RxDoctor Payments Data

Addison Voth, APRN

Family · Newton, KSNPI 1013378215

Payments from drug & device makers

$3,897in general payments, 2019–2025

Across 259 payments — averaging $15.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Lilly USA, LLC$518
  • Pfizer$436
  • AstraZeneca$322
  • Amgen$298
  • Bayer$212
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$3,883100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,897 in reported general payments places this provider in the 90th percentile of 1,579 family providers in Kansas.

See all family providers in Kansas

Medicare billing

Part B allowed, 2024
$49,147
Medicare patients
243
Services billed
719

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide29$39,549
MounjaroTirzepatide12$18,097
EliquisApixaban27$17,586
Tresiba Flextouch U-100Insulin Degludec11$3,363
SynthroidLevothyroxine Sodium13$1,315
Bupropion XlBupropion Hcl18$875
Nebivolol Hcl12$806
Atorvastatin Calcium125$720
Albuterol Sulfate HfaAlbuterol Sulfate26$675
Omeprazole76$618
Duloxetine Hcl36$597
Pantoprazole Sodium64$572
Oxybutynin Chloride ErOxybutynin Chloride16$525
Levothyroxine Sodium111$518
Losartan Potassium99$499

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$203$39,54929 claims
Lilly USA, LLCMounjaro$518$18,09712 claims
PfizerEliquis$436$17,58627 claims
AbbVieSynthroid$1,066$1,31513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,579 family providers in Kansas.

Other family in Newton

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →